We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturing methods used by Pfizer to produce its top-selling hypertension treatment drug Norvasc do not infringe on patents held by Synthon, a federal district court has ruled.
The invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer’s blockbuster cholesterol-lowering drug, Lipitor.
A company’s right to challenge a patent that it is licensed to use is not restricted by the licensing agreement between it and the patent holder, the U.S. Supreme Court said in a Jan. 9 ruling.
Plaintiffs are asking the Supreme Court to review the dismissal of a case to determine the legality of reverse-payment agreements, where brand drugmakers pay generic rivals to keep their low-cost versions of prescription products off the market.
Despite being the first to win final FDA approval — with 180-days of exclusivity — to manufacture and market generic Focalin, Teva Pharmaceutical still has to prevail in court against Novartis and Celgene.
Apotex wants legal protection from patent infringement liabilities related to the manufacturing and marketing of ranitidine hydrochloride, a generic version of GlaxoSmithKline’s (GSK) Zantac, according to a complaint filed in federal court last week.
The invalidation of a key patent held by Pfizer could open the door to the manufacturing and marketing of atorvastatin tablets, a generic version of Pfizer’s blockbuster cholesterol-lowering drug, Lipitor.
The U.S. Court of Appeals for the Federal Circuit brushed off an eleventh-hour request by Apotex asking it to reverse a decision it made recently upholding a block on sales of generic Plavix.
Celgene has filed a patent infringement lawsuit in federal court to block the manufacturing and marketing of generic Thalomid, Barr Laboratories confirmed this week.
A court decision that said Abbott Laboratories did not intentionally infringe on a patented hepatitis C virus technology should be reversed, multiplying damages against the company, according to an appeal filed by patent holder Innogenetics.